K86

4-tert-butyl-N-[6-(2-hydroxyethyloxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-yl-pyrimidin-4-yl]benzenesulfonamide

Find entries where: K86

is present as a standalone ligand in 1 entries

Find related ligands:

Chemical Component Summary
Name	4-tert-butyl-N-[6-(2-hydroxyethyloxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-yl-pyrimidin-4-yl]benzenesulfonamide
Identifiers	4-~{tert}-butyl-~{N}-[6-(2-hydroxyethyloxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-yl-pyrimidin-4-yl]benzenesulfonamide
Formula	C₂₇ H₂₉ N₅ O₆ S
Molecular Weight	551.614
Type	NON-POLYMER
Isomeric SMILES	CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc2c(c(nc(n2)c3ncccn3)OCCO)Oc4ccccc4OC
InChI	InChI=1S/C27H29N5O6S/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24/h5-15,33H,16-17H2,1-4H3,(H,30,31,32)
InChIKey	GJPICJJJRGTNOD-UHFFFAOYSA-N

Chemical Details
Formal Charge	0
Atom Count	68
Chiral Atom Count	0
Bond Count	71
Aromatic Bond Count	24

Drug Info: DrugBank

DrugBank ID	DB00559
Name	Bosentan
Groups	investigational approved
Description	Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.
Synonyms	bosentán bosentan anhydrous Bosentan Bosentan monohydrate p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide bosentanum 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide
Brand Names	Sandoz Bosentan Bosentan Tablets Bosentan Accel-bosentan Nat-bosentan Apo-bosentan Auro-bosentan Mar-bosentan Bio-bosentan Stayveer Taro-bosentan Teva-bosentan Tracleer PMS-bosentan Alembic-bosentan Mylan-bosentan Act Bosentan
Indication	Used in the treatment of pulmonary arterial hypertension (PAH), to improve exercise ability and to decrease the rate of clinical worsening (in patients with WHO Class III or IV symptoms).
Categories	Amides Antihypertensive Agents Antihypertensives for Pulmonary Arterial Hypertension Benzene Derivatives Benzenesulfonamides BSEP/ABCB11 Inhibitors Cardiovascular Agents Cytochrome P-450 CYP2C9 Inducers Cytochrome P-450 CYP2C9 Inducers (moderate) Cytochrome P-450 CYP2C9 Substrates Cytochrome P-450 CYP3A Inducers Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Inducers Cytochrome P-450 CYP3A4 Inducers (moderate) Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 Enzyme Inducers Cytochrome P-450 Substrates Endothelin Receptor Antagonists Genito Urinary System and Sex Hormones Gynecological Antiinfectives and Antiseptics Hepatotoxic Agents OATP1B1/SLCO1B1 Substrates Pyrimidines Sulfonamides Sulfones Sulfur Compounds Vasodilating Agents
ATC-Code	G01AE10 C02KX01
CAS number	147536-97-8

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
Endothelin B receptor	MQPPPSLCGRALVALVLACGLSRIWGEERGFPPDRATPLLQTAEIMTPPT...	unknown	antagonist
Endothelin-1 receptor	METLCLRASFWLALVGCVISDNPERYSTNLSNHVDDFTTFRGTELSFLVT...	unknown	antagonist
Cytochrome P450 3A4	MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...	unknown	substrate,inducer
Cytochrome P450 2C9	MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDI...	unknown	substrate,inducer
Bile salt export pump	MSDSVILRSIKKFGEENDGFESDKSYNNDKKSRLQDEKKGDGVRVGFFQL...	unknown	inhibitor

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682